- Home
- RLAY
as 11-05-2025 11:01am EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Upcoming Earnings Alert:
Get ready for potential market movements as Relay Therapeutics Inc. RLAY prepares to release earnings report on 06 Nov 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 803.4M | IPO Year: | 2020 |
| Target Price: | $17.25 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $7.64 | Next Earning Date: | 11-06-2025 |
| Revenue: | $8,355,000 | Revenue Growth: | -76.27% |
| Revenue Growth (this year): | 27.3% | Revenue Growth (next year): | 7.43% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sanjiv | RLAY | President and CEO | Nov 3 '25 | Sell | $7.00 | 62,073 | $434,511.00 | 703,215 | |
| Rahmer Peter | RLAY | See remarks | Oct 29 '25 | Sell | $7.50 | 21,394 | $160,455.00 | 337,469 | |
| Bergstrom Donald A | RLAY | President, R&D | Oct 28 '25 | Sell | $7.29 | 30,897 | $225,239.13 | 521,823 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Oct 28 '25 | Sell | $7.29 | 21,664 | $157,930.56 | 313,631 | |
| Rahmer Peter | RLAY | See remarks | Oct 28 '25 | Sell | $7.29 | 19,135 | $139,494.15 | 337,469 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
Zacks
6 days ago
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet
Zacks
8 days ago
Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy
Insider Monkey
a month ago
Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608
Simply Wall St.
2 months ago
Barfresh Food Group Among 3 Promising Penny Stocks
Insider Monkey
2 months ago
Guggenheim Gives Buy Rating to Relay Therapeutics (RLAY)
Motley Fool
2 months ago
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week
Insider Monkey
4 months ago
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.